[ad_1]
[앵커]
With the spread of Corona 19 in the United States in earnest, President-elect Joe Biden held a video conference with medical staff to discuss the measures. Health Minister Alix Aza says that by the end of the year two types of vaccines will be available in 40 million doses. Let’s connect Washington and learn more. Correspondent Taewook Kang! While President Trump is silent, is Biden’s move actively taking place? Today, you started caring for Corona 19, right? Biden-elect held a video conference with medical staff. Medical staff said the medical scene was on the brink of collapse with a recent flood of patients. In particular, they complained that the local health insurance system was at risk due to a lack of timely financial support. In response, President-elect Biden said that after President Trump left the White House, Republican lawmakers agreed to cooperate with financial aid. In particular, he explained that the stimulus will continue to provide financial support to state and local governments. He also stressed that when he begins serving as the new president, he will be the first to prepare funds to support each state. This appears to mean that the new administration will play an active role in getting Congress to discuss massive stimulus legislation again.
The Trump administration’s high-speed vaccine development team also held a press conference, right? You can get 40 million shots by the end of this year, right?
[기자]A press conference was held by the so-called ‘Operation Ultrafast’ team in charge of developing vaccines and treatments for the US administration.
Health Minister Alix Aza says there will be 40 million doses of vaccine available by the end of this year.
In particular, he explained that it is the amount that can be vaccinated against 20 million people who are vulnerable to the virus and there are two vaccines.
It appears that two types of vaccines are in development, one developed by Pfizer and Bioentech, and the vaccine being developed by Modena, where the results of the recent phase 3 clinical trial were announced.
In this regard, Ugur Sahin, CEO of Bioentech, announced that he will apply for emergency use approval to the US FDA for the 20th local time.
Sahin also added that the company is currently working on a recipe that allows the vaccine to be stored at room temperature.
YTN Taewook Kang in Washington[[email protected]]it is.
[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]